News from isis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 10, 2014, 04:30 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants...

Oct 09, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned an $18 million milestone payment from GlaxoSmithKline (GSK)...

Oct 02, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Webcast and conference call to provide an update on...

Oct 01, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $1.5 Million From GSK for the Advancement of ISIS-GSK4 Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1.5 million milestone payment from GSK related to the...

Sep 24, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at...

Sep 17, 2014, 07:26 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has earned a $4 million milestone payment from Achaogen, Inc. (NASDAQ: AKAO) associated...

Sep 03, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

Sep 02, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from three drugs in its lipid franchise were highlighted in four presentations...

Aug 28, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial...

Aug 15, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the...

Aug 04, 2014, 08:30 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Reports Financial Results and Highlights for Second Quarter 2014

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss...

Aug 01, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with...

Jul 28, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2014 Financial...

Jul 17, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)

 Isis Pharmaceuticals, Inc.  (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)Rx in patients with high...

Jul 16, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related...

Jul 02, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the...

Jun 24, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to...

Jun 17, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the...

Jun 16, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2...

Jun 12, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Present at the 2014 Wells Fargo Healthcare Conference

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...